Hints and tips:
...Endo’s projected 2022 ebitda is set to be half its level of last year, leaving its debt-to-cash flow ratio at 10 times....
...In Invisible Women, the FT business book of the year 2019, Caroline Criado Perez spends a chapter chronicling the failure by the pharmaceuticals industry, data collectors and healthcare system in addressing...
...Teva separately received a boost on Tuesday when the company, along with Johnson & Johnson, Endo International, and Allergan, won a case related to the US opioid addiction crisis....
...Its case against Endo, Teva, and Allergan is currently being tried in state court. The settlement payments to New York will begin this summer and continue over the next 17 years....
...James added that the pharmaceutical company’s heavy marketing of opioids was partially motivated by quotas for sales staff....
...Johnson & Johnson, Teva, Endo and AbbVie’s Allergan are accused of falsely marketing painkillers and knowingly underplaying the risk of addiction in order to increase sales, in litigation brought by three...
...Moreover, it collected millions of dollars designing and implementing marketing campaigns for three other opioid manufacturers — Johnson & Johnson, Endo Pharmaceuticals and Mallinckrodt — the lawsuits found...
...Endo International, a pharmaceutical company, fell 9 per cent to $2.65; Teva, the Israeli drugmaker, lost 4.6 per cent to $7.08; and McKesson, another distributor, fell 3 per cent to $142.55 in late-morning...
...It has requested that one opioid — Opana ER, made by Endo Pharmaceuticals — be removed from the market because of patterns of abuse, but also approved Dsuvia, by AcelRx Pharmaceuticals, another fast-acting...
...Teva Pharmaceuticals, the only remaining manufacturer, fell 1.6 per cent to $7.38, after losing 3.5 per cent during the trading day....
...Pharmaceutical companies Endo International settled both cases for $10m, Johnson & Johnson for $20m and Mallinckrodt for $30m....
...The news hit the shares of other companies embroiled in litigation such as Teva, Endo and Mallinckrodt. Some investors expect further falls....
...Teva, the Israeli drugmaker, closed down 9.6 per cent, pharmaceutical company Endo International was down 12.4 per cent, and McKesson, a drug distributor, was lower by 5.7 per cent....
...Shares in Mallinckrodt fell 7 per cent on Monday; Endo’s fell by 17 per cent. Endo, which also plans a vigorous defence, withdrew its opioid medication Opana in June 2017....
...McKesson has said it maintains strong programmes designed to detect and prevent opioid diversion within the pharmaceutical supply chain. Endo denies the allegations....
...Over three months, Teva’s share price has dropped 15 per cent, while Endo and Insys have fallen by nearly a half. The S&P 500 pharmaceuticals index is down 4 per cent over the same period....
...Rhodes Pharmaceuticals was set up in 2007, four months after Purdue pleaded guilty to federal criminal charges that it had mis-marketed OxyContin over the previous decade....
...seventh largest opioid manufacturer in the US, just behind generic drugmaking giant Teva, and well ahead of many of the other companies targeted in the recent wave of litigation, such as Johnson & Johnson, Endo...
...The system would probably be paid for by the makers of opioid painkillers, such as privately held Purdue Pharma, Endo and Depomed, which have faced criticism for fuelling the crisis by failing to warn of...
...Shares of Irish drugmaker Endo Pharmaceuticals fell sharply in after-hours trading on Thursday, after US regulators requested that it pull a reformulated version of its opiod pain medication Opana ER from...
...The new system would probably be funded by the pharmaceutical groups that manufacture opioid medicines — such as Perdue Pharma, Endo and Depomed — which have been sharply criticised for fuelling the crisis...
...Among the most commonly named defendants are drugmakers such as Purdue Pharmaceuticals, which is privately owned, Johnson & Johnson, Allergan, Mallinckrodt, Endo and Teva; distributors such as McKesson,...
...The lawsuit claims that five drugmakers — Purdue, which makes OxyContin, Endo, Johnson & Johnson, Teva and Allergan — committed fraud and other offences by knowingly downplaying the dangers of opioids, and...
...But if these cases do go through court, it might force more transparency in the pharmaceutical sector....
...Mr Campanelli previously served as chief executive of Par Pharmaceutical and joined Endo after the company bought Par in 2015....
International Edition